ライフサイエンスコーパス: fixed dose

1 scalated dosing than among those receiving a fixed dose.

2 be either a dose proportional to weight or a fixed dose.

3 also received s.c. injections of GM-CSF at a fixed dose.

4 ergy, requiring a lower current to achieve a fixed dose.

5 , a higher current was required to achieve a fixed dose.

6 randomized to receive darbepoetin given as a fixed dose (0.45 ug/kg every 4 weeks) versus administere

7 Shaking behavior caused by a fixed dose (2.5mg/kg) of icilin was also inhibited in a

8 ts were randomly assigned (1:1) to switch to fixed-dose 200 mg emtricitabine with 10 mg or 25 mg teno

9 Dosing schema varied and were either a fixed dose (6 [29%]) or based on body weight (10 [48%])

10 Two dosing scenarios were investigated: fixed dose (80 mg of febuxostat daily, 0.80 success rate

11 Children received hydroxyurea at a fixed dose (94 children; mean [+/-SD] age, 4.6+/-1.0 yea

12 reviously demonstrated anemia advantage with fixed dose administration.

13 Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, m

14 enous acetylcysteine has been delivered at a fixed dose and duration of 300 mg/kg over 20 to 21 hours

15 are generally limited to a single drug at a fixed dose and frequency.

16 heparins in many patients, are prescribed in fixed doses and do not need any coagulation monitoring i

17 n routine clinical practice because of their fixed dosing and favourable pharmacological profiles.

18 farin (n=404), warfarin (n=408; 324 [79%] on fixed-dose and 84 [21%] on dose-adjusted) did not reduce

19 used did not differ (24.1% and 24.4% for the fixed-dose and titration-dose group, respectively), with

20 antially reduced residual albuminuria during fixed dose angiotensin-converting enzyme inhibition.

21 Compared to a fixed-dose approach, the clinical algorithm provided sig

22 le-blind trial, we compared hydroxyurea at a fixed dose (approximately 20 mg per kilogram of body wei

23 .23 mg/m(2), which was converted to a 4.0 mg fixed dose based on population pharmacokinetic results.

24 ofemoral deep vein thrombosis treated with a fixed-dose catheter thrombolysis regimen, the addition o

25 The use of fixed-dose chemotherapy is rarely justified, but the Pan

26 ouble-blind, placebo-controlled, randomized, fixed-dose clinical trial evaluating the efficacy of GSK

27 manufacturing licenses for large numbers of fixed dose combination (FDC) drugs had been issued by st

28 Patients will receive different number of fixed dose combination (FDC) tablets according to their

29 osterone antagonist eplerenone in 2003 and a fixed dose combination of hydralazine-isosorbide dinitra

30 Patients will receive different number of fixed dose combination tablets according to their weight

31 Dapagliflozin (Farxiga), alone, or in the fixed dose combination with metformin (Xigduo), is an or

32 Fixed dose combination, or polypill, therapy has been sh

33 blind treatment with nebivolol and valsartan fixed-dose combination (5 and 80 mg/day, 5 and 160 mg/da

34 n with other antiretroviral agents) and as a fixed-dose combination (DOR/3TC/TDF), demonstrated nonin

35 tigated efficacy and safety of a once-daily, fixed-dose combination (FDC) of netarsudil and latanopro

36 aclatasvir at 60 mg were coformulated into a fixed-dose combination (FDC) tablet (Sovodak, Rojan Phar

37 dose-confirmation stage and then as a single fixed-dose combination (FDC) tablet.

38 patasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) fixed-dose combination (FDC), an interferon-free, comple

39 At week 8, the fixed-dose combination 20 and 320 mg/day group had signi

40 ir, emtricitabine, and tenofovir alafenamide fixed-dose combination [bictegravir group] and 330 with

41 With the fixed-dose combination alone, response rates were 93% (9

42 afety of a 3-day supervised treatment of the fixed-dose combination artesunate-amodiaquine Winthrop((

43 assigned participants (1:1) to receive oral fixed-dose combination bictegravir 50 mg, emtricitabine

44 The fixed-dose combination dispersible tablet of arterolane

45 atistical comparison was between the highest fixed-dose combination dose and the highest monotherapy

46 The cross-sectional FOCUS (Fixed-Dose Combination Drug for Secondary Cardiovascular

47 iretroviral therapy is switched from generic fixed-dose combination efavirenz-containing regimens to

48 med to further assess safety and efficacy of fixed-dose combination emtricitabine with tenofovir alaf

49 ears and older receiving regimens containing fixed-dose combination emtricitabine with tenofovir diso

50 nucleotide polymerase inhibitor, as a single fixed-dose combination for 12 weeks.

51 predose pertuzumab concentration) within the fixed-dose combination for subcutaneous injection versus

52 ion group vs 35 [14%] of 248 patients in the fixed-dose combination group), decreased neutrophil coun

53 group and acute myocardial infarction in the fixed-dose combination group); neither death was related

54 he intravenous infusion group and 248 to the fixed-dose combination group.

55 infusion group and 26 (10%) patients in the fixed-dose combination group.

56 terol, added to fluticasone propionate, in a fixed-dose combination in children.

57 omes can be conveniently treated with triple fixed-dose combination inhaler therapy with an inhaled c

58 Nebivolol and valsartan fixed-dose combination is an effective and well-tolerate

59 emtricitabine and tenofovir alafenamide as a fixed-dose combination is recommended for treatment of H

60 We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12

61 ty-assured generic medicines, development of fixed-dose combination medicines, and promotion of adher

62 The use of fixed-dose combination nucleoside reverse-transcriptase

63 underwent randomization for treatment with a fixed-dose combination of 180 mg of pyronaridine and 60

64 dolutegravir with matching placebo plus the fixed-dose combination of 200 mg emtricitabine and 25 mg

65 ty of QVA149 (indacaterol/glycopyrrolate), a fixed-dose combination of a long-acting beta2-agonist (i

66 We assessed the efficacy and safety of a fixed-dose combination of a vasodilating beta blocker (n

67 The efficacy and safety of fixed-dose combination of AM and PQP was comparable to A

68 Glecaprevir/pibrentasvir is a fixed-dose combination of an NS3/4A protease inhibitor a

69 The fixed-dose combination of any two antihypertensive drugs

70 A fixed-dose combination of arterolane maleate (AM), a new

71 The fixed-dose combination of bictegravir, emtricitabine, an

72 ents received twice-daily treatment with the fixed-dose combination of daclatasvir (30 mg), asunaprev

73 Patients received a twice-daily fixed-dose combination of daclatasvir, 30 mg; asunaprevi

74 In IPT clusters, participants received the fixed-dose combination of dihydroartemisinin-piperaquine

75 Patients were given an oral, once-daily, fixed-dose combination of EBR/GZR 50 mg/100 mg for 12 we

76 inetics, and efficacy of this single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtr

77 The single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtr

78 INTERPRETATION: The fixed-dose combination of elvitegravir, cobicistat, emtr

79 he ribavirin-free, direct-acting, antiviral, fixed-dose combination of glecaprevir/pibrentasvir (G/P)

80 eive treatment for 8, 12, or 16 weeks with a fixed-dose combination of grazoprevir, ruzasvir, and upr

81 ed for smoking status) to once-daily QVA149 (fixed-dose combination of indacaterol 110 mug and glycop

82 Fixed-dose combination of isosorbide dinitrate and hydra

83 ver before treated for HCV were prescribed a fixed-dose combination of ledipasvir (90 mg) and sofosbu

84 INTERPRETATION: The rate of cure with a fixed-dose combination of ledipasvir-sofosbuvir for pati

85 The phase 3 ION studies evaluated a fixed-dose combination of ledipasvir/sofosbuvir +/- riba

86 ncluding lopinavir (LPV) ISNP granules and a fixed-dose combination of LPV/ritonavir (RTV) ISNP granu

87 termittent preventive treatment (IPT) with a fixed-dose combination of mefloquine-artesunate (MQAS) o

88 ollowed by 6 mg/kg maintenance doses) or the fixed-dose combination of pertuzumab and trastuzumab for

89 The study met its primary endpoint: the fixed-dose combination of pertuzumab and trastuzumab for

90 s to develop a nanotechnology to formulate a fixed-dose combination of poorly water-soluble drugs in

91 sis were randomly assigned to groups given a fixed-dose combination of SOF and LDV, with RBV (n = 9)

92 rhosis were randomly assigned to an all-oral fixed-dose combination of sofosbuvir (400 mg) and velpat

93 atients with decompensated cirrhosis given a fixed-dose combination of sofosbuvir and velpatasvir wit

94 The fixed-dose combination of sofosbuvir plus ledipasvir was

95 These findings suggest that the fixed-dose combination of sofosbuvir-ledipasvir alone or

96 y, we evaluated the efficacy and safety of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg

97 A fixed-dose combination of sofosbuvir-velpatasvir-voxilap

98 oral dolutegravir 50 mg; or once-daily oral fixed-dose combination of tenofovir disoproxil fumarate

99 itive participants to trial clinics for ART (fixed-dose combination of tenofovir, emtricitabine, and

100 sess the efficacy and safety of an all-oral, fixed-dose combination of the hepatitis C virus NS5A inh

101 and safety of an interferon-free regimen--a fixed-dose combination of the nucleotide polymerase inhi

102 nofovir-emtricitabine in a 245 mg and 200 mg fixed-dose combination once daily, plus 800 mg darunavir

103 regimens, including combinations of DAAs and fixed-dose combination pills.

104 A fixed-dose combination polypill might improve cardiovasc

105 he growing body of clinical evidence for the fixed-dose combination regimen of elbasvir plus grazopre

106 ive sofosbuvir-velpatasvir, in a once-daily, fixed-dose combination tablet (134 patients), or sofosbu

107 andomly (1:1) to receive 12 or 24 weeks of a fixed-dose combination tablet containing ledipasvir and

108 merase inhibitor sofosbuvir in a once-daily, fixed-dose combination tablet for 12 weeks, ledipasvir-s

109 Patients were given a fixed-dose combination tablet of 90 mg ledipasvir and 40

110 ive and 22 treatment experienced) received a fixed-dose combination tablet of 90 mg of ledipasvir and

111 All patients received the fixed-dose combination tablet of LDV-SOF once-daily plus

112 ype 3 were randomly assigned to groups given fixed-dose combination tablet of ledipasvir and sofosbuv

113 The first received a fixed-dose combination tablet of ledipasvir-sofosbuvir (

114 e III studies, treatment with the once-daily fixed-dose combination tablet of ledipasvir/sofosbuvir (

115 were randomized to receive treatment with a fixed-dose combination tablet of sofosbuvir-velpatasvir-

116 io to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 weeks, l

117 grazoprevir 100 mg plus elbasvir 50 mg in a fixed-dose combination tablet once daily for 12 weeks.

118 NS5A inhibitor velpatasvir in a once-daily, fixed-dose combination tablet or matching placebo for 12

119 ceived sofosbuvir-velpatasvir (400 mg/100 mg fixed-dose combination tablet) and GS-9857 (100 mg) once

120 th trimethoprim-sulfamethoxazole in a single fixed-dose combination tablet), 12 weeks of fluconazole,

121 weight bands corresponding to the number of fixed-dose combination tablets [75 mg rifampicin, 50 mg

122 ts were randomly assigned to once-daily oral fixed-dose combination tenofovir alafenamide 25 mg and e

123 ily oral dolutegravir 50 mg; once-daily oral fixed-dose combination tenofovir disoproxil fumarate 300

124 (interquartile range, 0.91-2.13), mostly on fixed-dose combination tenofovir/emtricitabine/efavirenz

125 A fixed-dose combination therapy (polypill strategy) has b

126 Is fixed-dose combination therapy (polypill) that combines

127 Treatment with ICS/LABA fixed-dose combination therapy appeared to perform as we

128 sterol-lowering, antithrombotic therapy, and fixed-dose combination therapy.

129 emtricitabine and tenofovir alafenamide as a fixed-dose combination to dolutegravir administered with

130 emtricitabine and tenofovir alafenamide as a fixed-dose combination versus coformulated dolutegravir,

131 ant human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab, trastuzumab, an

132 Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a s

133 olving children with asthma, salmeterol in a fixed-dose combination with fluticasone was associated w

134 to assess the efficacy and safety of SOF/LDV fixed-dose combination without RBV in patients with HCV

135 d sofosbuvir-velpatasvir (400 mg/100 mg in a fixed-dose combination) plus GS-9857 (100 mg) once daily

136 irus (HCV) genotype 1 and 4 infections, as a fixed-dose combination.

137 irus (HCV) genotype 1 and 4 infections, as a fixed-dose combination.

138 de reverse transcriptase inhibitor (NRTI) in fixed-dose combination.

139 drug combination in a larger population as a fixed-dose combination.

140 e, zidovudine, or abacavir as dual or triple fixed-dose-combination paediatric tablets with lamivudin

141 Fixed dose combinations (FDC) with the advantage of once

142 LAMA/LABA fixed dose combinations (FDCs) provide the convenience o

143 arisons were also significant, favouring the fixed-dose combinations (all p<0.0001).

144 The use of fixed-dose combinations (FDC) has been shown to improve

145 The use of fixed-dose combinations (FDCs) improves adherence in sev

146 rst-line treatment for HIV, and coformulated fixed-dose combinations are preferred to facilitate adhe

147 Fixed-dose combinations could reduce pill burdens and co

148 Fixed-dose combinations have shown a positive effect on

149 lability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, t

150 Procurement of generic fixed-dose combinations increased from 33.3% (95% CI, 33

151 However, development of fixed-dose combinations of poorly water-soluble drugs fo

152 s kind of novel nanotechnology for pediatric fixed-dose combinations of poorly water-soluble drugs.

153 stable, and flexible pediatric granules for fixed-dose combinations that can be used as sachets and

154 uted; antiretroviral therapy initiation with fixed-dose combinations without bedaquiline drug interac

155 with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent d

156 randomly assigned to receive a single daily fixed-dose (Dactavira plus, n = 11) or the standard of c

157 randomly assigned to receive a single daily fixed-dose (Dactavira, n = 25) or the standard of care [

158 We tested the effects of 4-week fixed-dose daily adjunctive modafinil (MOD) 200 mg, in a

159 pies/mL were randomized (1:1) to once-daily, fixed-dose DOR at 100 mg, lamivudine at 300 mg, and teno

160 e-of-three in drug co-prescription or making fixed-dose drug combination.

161 -1 RNA <50 copies/mL to switch to once-daily fixed-dose DTG/3TC or remain on a tenofovir alafenamide

162 With its safety advantages, fixed-dose emtricitabine with tenofovir alafenamide has

163 The MTD of cediranib was 12 mg/m(2)/d (adult fixed dose equivalent, 20 mg).

164 semaglutide (doses reached after following a fixed dose-escalation regimen) or once-daily insulin gla

165 otine (0, 0.5, 1.0 mg) across three separate fixed dose experimental sessions.

166 EC-Asnase, administered as a 25,000 IU/m(2) fixed dose (FD) or individualized dose (ID) starting at

167 To investigate whether fixed-dose ferric citrate coordination complex favorably

168 end point and hospitalization, suggest that fixed-dose ferric citrate coordination complex has an ex

169 The beneficial effects of fixed-dose ferric citrate coordination complex on bioche

170 ponse duration of low-dose rituximab (100 mg fixed dose for 4 weekly infusions) together with a short

171 rely justified, but the Panel does recommend fixed dosing for a few select agents.

172 or placebo given at 0, 24, and 48 h, with a fixed-dose furosemide regimen as background therapy.

173 Oral, once-daily, fixed-dose grazoprevir 100 mg/elbasvir 50 mg for 12 week

174 dian hemoglobin (9.9 g/dl) compared with the fixed-dose group (9.4 g/dl).

175 as compared with 37% of the children in the fixed-dose group (P<0.001).

176 bil at 12 weeks was 200 (SD 71) ng/mL in the fixed-dose group and 318 (129) ng/mL in the pharmacokine

177 The fixed-dose group had a significantly lower median cumula

178 e 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg t

179 There were 379 patients randomized to the fixed-dose group, and 377 to the titration-dose group.

180 s of single vasodilators, usually given in a fixed dose, have not improved outcomes in patients with

181 5% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (

182 on had superior clinical efficacy to that of fixed-dose hydroxyurea, with equivalent safety.

183 stically significant decreases in the use of fixed-dose ICS-LABA agents in children (-0.98 percentage

184 pen-label noninferiority study that compared fixed-dose idraparinux with adjustable-dose oral vitamin

185 usted doses may be a better alternative to a fixed dose in future studies.

186 We recommend a fixed dose in patients >=100 kg (ie, 300 or 500 mg rathe

187 oterol maintenance and reliever therapy with fixed-dose inhaled corticosteroid/long-acting beta2-agon

188 ions delivered with a standard linear (LET) (fixed dose intensity per session for 160 min/wk) or nonl

189 an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromb

190 n with CS maintained up to 6 months, Tac and fixed-dose MMF (2 g/d) (arm B).

191 The fixed-dose, modified rheumatoid arthritis protocol for r

192 Overall, IV/oral delafloxacin fixed-dose monotherapy was non-inferior to IV vancomycin

193 age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no

194 Once-daily dolutegravir in combination with fixed-dose NRTIs represents an effective new treatment o

195 The fixed dose of 1,400 mg SC rituximab predicted by using s

196 Stage 1 data predicted that a fixed dose of 1,400 mg SC rituximab would result in a se

197 In phase 2, 20 patients received a fixed dose of 1000 mg (days 1, 8, and 15 of cycle 1; day

198 -intensified treatment with (131)I-MIBG at a fixed dose of 11.1 GBq (300 mCi) per cycle is safe and o

199 by slow intravenous injection, followed by a fixed dose of 15 000 IU/m(2) bleomycin by intravenous in

200 challenged on day 0, 14 and 28 with a single fixed dose of 2.5 grams of the following (random order):

201 hylcarbamazine, 6 mg/kg; plus albendazole, a fixed dose of 400 mg) or with DA alone.

202 Children with MDS received a fixed dose of 5 mg/m(2)/dose.

203 , followed by 4 maintenance infusions with a fixed dose of 500 mg at 3, 6, 9, and 12 months (n = 77),

204 Use of an empiric fixed dose of 750 mg of daptomycin is predicted to achie

205 .225, 0.45, 0.9, or 1.8 mg per kilogram or a fixed dose of 80 mg).

206 ent in which infected fish were exposed to a fixed dose of a common trematode parasite.

207 ed that increasing amounts of SAM added to a fixed dose of BUP resulted in dose-dependent reductions

208 S that were inhibited by pretreatment with a fixed dose of clonidine (0.15 mg/kg, s.c.).

209 hyperthermia and hyperactivity induced by a fixed dose of cocaine (15 mg/kg, i.p.).

210 This suggests that a low fixed dose of darbepoetin may be used as an alternative

211 th total body irradiation (TBI) were given a fixed dose of donor T cells (HSCT step 1), followed by c

212 FR<=20 ml/min per 1.73 m(2) 2:1 to receive a fixed dose of ferric citrate coordination complex (two t

213 In the context of CY tolerization, a high, fixed dose of haploidentical T cells was associated with

214 r stage IV melanoma were randomly assigned a fixed dose of ipilimumab of either 10 mg/kg (n=73), 3 mg

215 In conclusion, a fixed dose of riluzole (100 mg/day) did not show adjunct

216 umab, coadministration of trastuzumab with a fixed dose of T-DM1 at 3:1 and 8:1 ratios dramatically i

217 ng doses of ipilimumab in combination with a fixed dose of the PSA-Tricom vaccine.

218 fety of pharmacological prevention with low, fixed doses of anticoagulant drugs, prophylaxis remains

219 response technology, to receive one of three fixed doses of deutetrabenazine (12 mg/day, 24 mg/day, o

220 ss the efficacy, safety, and tolerability of fixed doses of deutetrabenazine-a novel vesicular monoam

221 , randomised controlled trials that examined fixed doses of five selective serotonin reuptake inhibit

222 day for 3 days), coupled with our historical fixed doses of fludarabine and rituximab (BFR), as a non

223 Regimens that infuse fixed doses of insulin with high rates of glucose are us

224 of oral umbralisib (400, 600, or 800 mg) and fixed doses of intravenous ublituximab (900 mg) and oral

225 nd treatment of either placebo or one of two fixed doses of oral, once-daily bitopertin (10 or 20 mg

226 revention, some have advocated administering fixed doses of statins based on a person's estimated net

227 zumab who were switched directly to 8-weekly fixed dosing of aflibercept without a loading phase.

228 Fixed dosing of mycophenolate consistently leads to unde

229 rch 5, 2015, we enrolled 150 patients in the fixed-dose omecamtiv mecarbil group and 149 in the pharm

230 dosing strategy applied varies markedly from fixed dosing ("one-dose-fits-all"), to mycophenolic acid

231 it of warfarin randomly assigned patients to fixed-dose or dose-adjusted warfarin groups.

232 ponse system to 26 weeks of monotherapy with fixed-dose oral cariprazine (3 mg, 4.5 mg [target dose],

233 All participants received the available fixed-dose oral formulation of elvitegravir 150 mg, cobi

234 Dabigatran is a fixed-dose, oral direct thrombin inhibitor with similar

235 Fixed-dose pembrolizumab (200 mg absolute, day 1, every

236 niazid should also be combined into a single fixed-dose pill, along with pyridoxine (vitamin B6), tha

237 These include new combination fixed-dose products, which may allow for greater flexibi

238 A fixed-dose protocol provided well-controlled INR only in

239 nts was simulated for 5 warfarin protocols-a fixed-dose protocol, a clinically guided protocol, and 3

240 Fixed-dose pyronaridine-artesunate was efficacious in th

241 Gemcitabine/cisplatin, fixed dose rate gemcitabine, gemcitabine/docetaxel, and

242 nd toxicity of gemcitabine administered at a fixed dose rate or in combination with cisplatin, doceta

243 Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have

244 Fixed-dose rate gemcitabine plus docetaxel achieves obje

245 Fixed-dose-rate gemcitabine and docetaxel achieved high

246 The combination of fixed-dose-rate gemcitabine and docetaxel has become an

247 Fixed-dose-rate gemcitabine and docetaxel is a reasonabl

248 For patients with disseminated disease, fixed-dose-rate gemcitabine plus docetaxel is an appropr

249 Providers noted the inflexibility of the fixed dose regimen, with dosages sometimes inappropriate

250 A fixed-dose regimen of apixaban alone was noninferior to

251 on and cirrhosis who received a 12-week oral fixed-dose regimen of daclatasvir, asunaprevir, and becl

252 received 12 weeks of treatment with the oral fixed-dose regimen of daclatasvir, asunaprevir, and becl

253 A fixed-dose regimen of rivaroxaban alone was noninferior

254 A fixed-dose regimen of rivaroxaban, an oral factor Xa inh

255 he level of anticoagulation in response to a fixed-dose regimen of warfarin is difficult to predict d

256 g to a single inhaler regimen (SMART) with a fixed-dose regimen with salbutamol as reliever ('Standar

257 ibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended tr

258 gned in a 1:1 ratio to the SMART or standard fixed-dose regimen.

259 But are such fixed-dose regimens optimal or can alternative regimens

260 Results using fixed-dose regimens showed a low incidence of rejection

261 Antibiotic treatment often follows fixed-dose regimens, with a standard dose of antibiotic

262 , could improve safety compared to the early fixed-dose regimens.

263 with the concentration of any odorant via a fixed dose-response function with a variable sensitivity

264 the dose instead of using the current single-fixed-dose scheme and, when combined with radiomic data,

265 For the fixed-dose, shock-dependent, and no hydrocortisone group

266 n 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone group

267 n (ACC/AHA) cholesterol guidelines recommend fixed-dose statin therapy for those at risk and do not r

268 No trial directly compared titrated vs fixed-dose statins, and there were no clear differences

269 usion for a titration-dose strategy versus a fixed-dose strategy for darbepoetin.

270 e-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with bipolar I disord

271 harmacokinetics, efficacy, and safety of the fixed-dose subcutaneous formulation compared to intraven

272 hm to intravenous rituximab (375 mg/m(2)) or fixed-dose subcutaneous rituximab (1400 mg), stratified

273 okinetic non-inferiority of 3 week cycles of fixed-dose subcutaneous rituximab versus standard intrav

274 The study regimen consisted of a fixed-dose tablet containing darunavir 800 mg, cobicista

275 release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB16), or matching pla

276 release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB32), sustained-relea

277 12 weeks followed by once daily combination fixed-dose tablets of 90 mg ledipasvir and 400 mg sofosb

278 The visual and anatomic improvements after fixed dosing through week 24 and PRN dosing with monthly

279 pace of possible treatment regimens (e.g. to fixed-dose treatments).

280 andomized, double-blind, placebo-controlled, fixed-dose trial using a sequential parallel comparison

281 Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis ad

282 Fixed-dose unmonitored treatment with dabigatran etexila

283 mized clinical trials of statins vs placebo, fixed-dose vs titrated statins, and higher- vs lower-int

284 nd with dose-adjusted warfarin compared with fixed-dose warfarin (16 vs 7, p=0.09).

285 However, compared with fixed-dose warfarin (n=471), dose-adjusted warfarin (n=4

286 ng chemotherapy through CVCs to no warfarin, fixed-dose warfarin 1 mg per day, or dose-adjusted warfa

287 During fixed dosing (weeks 12-52) all exudative features showed

288 improvements at week 52 following a year of fixed dosing with ranibizumab and IAI were maintained at

289 t that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including

290 doxaban, and rivaroxaban are administered in fixed doses without anticoagulant monitoring.

291 ban, rivaroxaban, and edoxaban) and given in fixed doses without coagulation monitoring.

292 Direct oral anticoagulants (DOACs) used in fixed doses without laboratory monitoring are the agents

293 asugrel, and ticagrelor, are administered in fixed doses without laboratory monitoring.

294 ction and the capacity to be administered in fixed doses without routine coagulation monitoring, NOAC

295 cal care because they can be administered in fixed doses without routine coagulation monitoring.

296 acological basis for their administration in fixed doses without routine coagulation monitoring.

297 icians should continue to prescribe NOACs in fixed doses without routine monitoring.

298 l fibrillation were developed to be given in fixed doses without the need for the routine monitoring

299 coagulant agents that can be administered in fixed doses, without laboratory monitoring and dose adju

300 et international normalized ratio 2 to 3) or fixed-dose ximelagatran 36 mg twice daily.